Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 5-amino-3-(4-(((5-fluoro-2-methoxybenzoyl)amino)methyl)phenyl)-1-((2s)-1,1,1-trifluoropropan-2-yl)pyrazole-4-carboxamide
2. Loxo-305
1. Loxo-305
2. 2101700-15-4
3. Pirtobrutinib [usan]
4. Jna39i7zvb
5. (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
6. Ly3527727
7. Rxc-005
8. Ly-3527727
9. 1h-pyrazole-4-carboxamide, 5-amino-3-(4-(((5-fluoro-2-methoxybenzoyl)amino)methyl)phenyl)-1-((1s)-2,2,2-trifluoro-1-methylethyl)-
10. 1h-pyrazole-4-carboxamide, 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(1s)-2,2,2-trifluoro-1-methylethyl]-
11. Btk Inhibitor 16
12. Unii-jna39i7zvb
13. Pirtobrutinib [inn]
14. Pirtobrutinib [jan]
15. Loxo305
16. Pirtobrutinib (loxo-305)
17. Pirtobrutinib [who-dd]
18. Chembl4650485
19. Schembl19014257
20. Gtpl11628
21. Glxc-25733
22. Ex-a5016
23. Who 11681
24. Bl180882
25. Hy-131328
26. Cs-0133286
27. Loxo-305;ly 3527727; Rxc-005
28. 5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-((2s)-1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
29. 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2s)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide
Molecular Weight | 479.4 g/mol |
---|---|
Molecular Formula | C22H21F4N5O3 |
XLogP3 | 3.3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 7 |
Exact Mass | 479.15805220 g/mol |
Monoisotopic Mass | 479.15805220 g/mol |
Topological Polar Surface Area | 125 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 719 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
About the Company : Sintaho Pharmaceutical Co., Ltd., located in Chongqing, China, contributes to being the most dependable partner for global pharmaceutical companies. Sintaho specializes in chemosyn...
About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...
About the Company : Founded in 2003, Hyderabad-based MSN Labs is one of the fastest-growing research-based pharmaceutical company in India. Boasting a diverse product portfolio, with multiple products...
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Pirtobrutinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pirtobrutinib, including repackagers and relabelers. The FDA regulates Pirtobrutinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pirtobrutinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pirtobrutinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pirtobrutinib supplier is an individual or a company that provides Pirtobrutinib active pharmaceutical ingredient (API) or Pirtobrutinib finished formulations upon request. The Pirtobrutinib suppliers may include Pirtobrutinib API manufacturers, exporters, distributors and traders.
click here to find a list of Pirtobrutinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pirtobrutinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pirtobrutinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pirtobrutinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pirtobrutinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pirtobrutinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pirtobrutinib suppliers with NDC on PharmaCompass.
Pirtobrutinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pirtobrutinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pirtobrutinib GMP manufacturer or Pirtobrutinib GMP API supplier for your needs.
A Pirtobrutinib CoA (Certificate of Analysis) is a formal document that attests to Pirtobrutinib's compliance with Pirtobrutinib specifications and serves as a tool for batch-level quality control.
Pirtobrutinib CoA mostly includes findings from lab analyses of a specific batch. For each Pirtobrutinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pirtobrutinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Pirtobrutinib EP), Pirtobrutinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pirtobrutinib USP).
LOOKING FOR A SUPPLIER?